New GE Healthcare will host a webinar on the uses of contrast media in echocardiology and an update on their contrast agent: Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP).  Please click here for more information and to register.

New GE Healthcare receives FDA approval to manufacture Optison™ in-house
GE Healthcare receives FDA approval to manufacture OptisonTM in-house, ensuring more consistent supply to the market. Read the full press release here.

New New TTE with contrast yielded lower mortality than non-contrast TTE in critically ill patients
More coverage of large new study showing safety and lower mortality rates of Contrast Enhanced Ultrasound (CEUS) in critically ill patients. Read more here.

Clicking on any of the above links will open a new browser window to a site that is not sponsored by ASE.  ASE is not responsible for the content located at this site.
The Basics News